Stephens Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)

Stock analysts at Stephens assumed coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a research report issued on Monday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $65.00 price target on the stock. Stephens’ price objective indicates a potential upside of 51.73% from the stock’s previous close.

Several other equities research analysts have also commented on the company. Truist Financial restated a “buy” rating and set a $53.00 target price (down previously from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Leerink Partnrs upgraded Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Leerink Partners restated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Monday, September 9th. Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a research report on Monday, August 26th. Finally, Morgan Stanley upped their target price on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 6th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $52.13.

Kymera Therapeutics Trading Up 1.0 %

NASDAQ KYMR opened at $42.84 on Monday. The business’s 50-day moving average price is $47.02 and its two-hundred day moving average price is $41.80. Kymera Therapeutics has a 12 month low of $18.89 and a 12 month high of $53.27. The firm has a market capitalization of $2.77 billion, a PE ratio of -18.31 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. During the same quarter in the previous year, the company posted ($0.90) EPS. The business’s revenue was down 20.9% on a year-over-year basis. As a group, analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Pamela Esposito sold 13,500 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. Company insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors have recently modified their holdings of KYMR. Price T Rowe Associates Inc. MD grew its holdings in shares of Kymera Therapeutics by 18.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock valued at $254,548,000 after acquiring an additional 996,300 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Kymera Therapeutics by 19.2% in the first quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after acquiring an additional 769,486 shares in the last quarter. Artal Group S.A. grew its holdings in shares of Kymera Therapeutics by 19.6% in the first quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after acquiring an additional 496,400 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Kymera Therapeutics by 85.8% in the third quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock valued at $37,754,000 after acquiring an additional 368,394 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Kymera Therapeutics by 7.2% in the third quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock valued at $218,587,000 after acquiring an additional 308,954 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.